Marek Disease (Marek's Disease)

A transmissible viral disease of birds caused by avian herpesvirus 2 (HERPESVIRUS 2, GALLID) and other MARDIVIRUS. There is lymphoid cell infiltration or lymphomatous tumor formation in the peripheral nerves and gonads, but may also involve visceral organs, skin, muscle, and the eye.

Also Known As:

Networked: 850 relevant articles (41 outcomes, 70 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Newcastle Disease
3.	Infection
4.	Tenosynovitis
5.	Influenza in Birds (Avian Flu)

Experts

1.	Nair, Venugopal: 17 articles (01/2014 - 08/2003)
2.	Osterrieder, Nikolaus: 15 articles (03/2013 - 08/2002)
3.	Smith, Lorraine P: 14 articles (06/2013 - 02/2006)
4.	Jarosinski, Keith W: 10 articles (10/2015 - 01/2005)
5.	Sharif, Shayan: 10 articles (01/2015 - 04/2006)
6.	Zhao, Yuguang: 10 articles (02/2011 - 07/2007)
7.	Gimeno, Isabel M: 8 articles (09/2015 - 02/2004)
8.	Cheng, Hans H: 8 articles (05/2015 - 01/2012)
9.	Yao, Yongxiu: 8 articles (01/2014 - 07/2007)
10.	Cortes, Aneg L: 7 articles (09/2015 - 12/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Marek Disease:

1.	VaccinesIBA 01/01/2012 - "Several highly efficacious vaccines are currently available for control of Marek's disease, a lymphoproliferative disease in chickens. " 04/01/2014 - "This study was designed to compare the protective efficacy of MDV-1 (CVI988/Rispens) and MDV-3 (HVT) vaccines against challenge of a very virulent plus strain of Marek's disease virus (vv+MDV) in experimental and commercial egg-layer lines of chickens under controlled experimental conditions. " 06/01/2015 - "However, HVT-based vaccines confer limited protection against challenge, with emergent very virulent plus Marek's disease virus (vv+MDV). " 06/21/1986 - "This first description of very virulent strains of Marek's disease virus from outside the USA suggests that at least some of the increasingly frequent disease outbreaks reported in Europe may be associated with such strains and that the adoption of bivalent or polyvalent vaccines containing, for example, attenuated Marek's disease virus plus herpesvirus of turkeys may be beneficial in the field." 01/01/2004 - "Earlier studies have shown that the B haplotype has a significant influence on the protective efficacy of vaccines against Marek's disease (MD) and that the level of protection varies dependent on the serotype of MD virus (MDV) used in the vaccine. "
2.	AntigensIBA 01/01/1980 - "Immunization trials with virus-free antigens against Marek's disease." 07/01/1978 - "An experiment was performed to study the immunogenicity of the dermal antigen of Marek's disease virus, extracted from the skin of 30-day-old chickens, infected with Marek's disease virus on the first day of life. " 01/01/1976 - "Studies were undertaken to determine the presence of lesions and immuno-fluorescent (IF) antigen of Marek's disease (MD) in the comb, wattles and skin overlaying the shank of MD affected birds. " 10/01/1973 - "Studies on intracellular and membrane antigens induced by Marek's disease virus." 01/01/1973 - "Immunoferritin studies of Marek's disease virus directed intracellular and membrane antigens."
3.	ganhuangenin (Sb 1)IBA 08/01/2010 - "Comparative efficacy of BAC-derived recombinant SB-1 vaccine and the parent wild type strain in preventing replication, shedding and disease induced by virulent Marek's disease virus." 04/01/1995 - "The field safety and efficacy of a bivalent Marek's disease (MD) vaccine (herpesvirus of turkeys + strain SB-1) administered in ovo were evaluated. " 04/01/1995 - "Field safety and efficacy of in ovo administration of HVT + SB-1 bivalent Marek's disease vaccine in commercial broilers." 10/01/1992 - "Previous studies have described an augmentation of avian leukosis virus (ALV)-induced lymphoid leukosis in chickens that were coinfected with a serotype 2 Marek's disease virus (MDV) strain, SB-1. " 07/01/1983 - "Field trials with a bivalent vaccine (HVT and SB-1) against Marek's disease."
4.	Glycoproteins (Glycoprotein)IBA 02/01/1996 - "Influence of chicken genotype on protection against Marek's disease by a herpesvirus of turkeys recombinant expressing the glycoprotein B (gB) of Marek's disease virus." 03/01/1992 - "Protection against Marek's disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus." 01/01/2013 - "Our previous study reported that both glycoproteins gB and gH of the herpesvirus Marek's disease virus (MDV) contain eleven potential heptad repeat domains. " 03/01/1996 - "Protection studies against Marek's disease using baculovirus-expressed glycoproteins B and C of Marek's disease virus type 1." 01/01/2013 - "Interaction domain of glycoproteins gB and gH of Marek's disease virus and identification of an antiviral peptide with dual functions."
5.	AntibodiesIBA 10/01/1982 - "Vaccination with turkey herpesvirus (HVT) of 18-day-old chicken embryos from a commercial source or from a cross (15 X 7) of two inbred lines induced better protection against early post-hatch challenge with virulent Marek's disease virus (MDV) than vaccination at hatch, despite the presence in embryos of maternally derived antibodies to HVT or to HVT and MDV. " 03/01/2004 - "An enzyme-linked immunosorbent assay (ELISA) for detection of Marek's disease virus-specific antibodies and its application in an experimental vaccine trial." 04/01/2006 - "To improve the protection efficiency of the recombinant Marek' s disease viruses (MDV) in chickens with or without maternal antibodies,the work of selecting the optimal promoters for the construction of recombinant MDV was carried out. " 03/01/2006 - "The presence of chicken anemia virus (CAV) in Slovenia was confirmed by inoculation of 1-day-old chickens without antibodies against CAV and isolation of the virus on the Marek's disease chicken cell-MSB1 line and by polymerase chain reaction (PCR). " 03/01/2004 - "An enzyme-linked immunosorbent assay (ELISA) for the detection of Marek's disease virus (MDV)-specific antibodies was developed. "
6.	Monoclonal AntibodiesIBA 04/01/1999 - "Monoclonal antibodies (MAbs) were prepared against ICP4 of Marek's disease virus (MDV). " 04/01/1990 - "Among the 33 monoclonal antibodies (MAbs) against pseudorabies virus (PRV) examined, three MAbs (24-17, 74-26, and 8) were found to react with cells infected with Marek's disease virus (MDV)-related viruses by immunofluorescence test. " 12/01/1986 - "Preparation of monoclonal antibodies against Marek's disease virus and herpesvirus of turkeys." 12/01/1984 - "Two hybridoma clones producing monoclonal antibodies were obtained from mice immunized with the Marek's disease (MD)-lymphoblastoid cell line MSB1. " 01/01/1984 - "A major virus-specific polypeptide antigenically cross-reactive between Marek's disease virus (MDV) and herpesvirus of turkeys (HVT) was characterized by two monoclonal antibodies against MDV. "
7.	Surface Antigens (Surface Antigen)IBA 01/01/1987 - "Evidence is presented that Marek's disease tumour-associated surface antigen is not involved in the antitumour responses. " 09/01/1982 - "Surface antigens on Marek's disease lymphoblastoid tumor cell lines." 01/01/1975 - "Detection of T-cell surface antigens in a Marek's disease lymphoblastoid cell line." 12/01/1972 - "Cell surface antigen on quail cells infected with herpesvirus of turkey or Marek's disease virus." 02/01/1970 - "Surface antigen on chick kidney cells infected with the herpesvirus of Marek's disease."
8.	DEAE-Dextran (Pulsar)IBA 07/01/1978 - "The study is continued, with particular emphasis on the relationship of DEAE-dextran to protection against Marek's disease."
9.	Neutralizing AntibodiesIBA 06/05/1978 - "[Significance of virus-neutralizing antibodies in Marek's disease of chickens. " 05/01/1974 - "Serum neutralizing antibody development and host resistance in chickens exposed to Marek's disease infection." 02/01/2007 - "Expression of IL-2 increased the neutralizing antibody response against HVT but did not increase the protection against virulent Marek's disease virus challenge." 07/01/1979 - "Inoculation of chickens with purified material also resulted in the production of precipitating and neutralizing antibody, showing that these high-molecular-weight polypeptides play a role in the humoral immunity to Marek's disease. " 11/21/1985 - "The virus-determined membrane antigen (MA) was proposed as immunogen because it was known to elicit naturally occurring virus-neutralizing antibodies in man and because analogous antigens had been shown to act as effective experimental vaccines for preventing the herpesvirus-induced lymphomas of Marek's disease in chickens. "
10.	DNA Primase (Primase)IBA 03/01/2015 - "The Mut UL5-I682R Marek's Disease Virus with a Single Nucleotide Mutation Within the Helicase-Primase Subunit Gene not only Reduces Virulence but also Provides Partial Vaccinal Protection Against Marek's Disease." 05/04/2015 - "Characterizing in vivo stability and potential interactions of a UL5 helicase-primase mutation previously shown to reduce virulence and in vivo replication of Marek's disease virus." 06/01/2014 - "Characterizing the molecular basis of attenuation of Marek's disease virus via in vitro serial passage identifies de novo mutations in the helicase-primase subunit gene UL5 and other candidates associated with reduced virulence." 01/01/2015 - "Addition of a UL5 helicase-primase subunit point mutation eliminates bursal-thymic atrophy of Marek's disease virus ∆Meq recombinant virus but reduces vaccinal protection."

Therapies and Procedures

1.	Transplants (Transplant) 03/01/1994 - "4. Significant line differences were found in graft-versus-host reaction competence and Marek's disease resistance. " 03/01/1984 - "The graft-versus-host reaction had a smaller coefficient of variation than the other two tests, and it was concluded that this test is likely to be the most reliable indicator of the outcome of infection with Marek's disease virus." 10/01/1978 - "Marek's disease virus-induced tumor transplants: development and rejection in various genetic strains of chickens." 01/01/1977 - "A continuous lymphoblastoid cell line was established from a JMV tumor transplant related to Marek's disease (MD). " 04/01/1976 - "1. Marek's disease tumor transplant (JMV)."
2.	Thymectomy 01/01/1997 - "Chickens rendered either CD4(+) or CD8(+) T-cell-deficient by thymectomy and subsequent inoculation of anti-CD4 or anti-CD8 monoclonal antibody (mAb), were infected with Marek's disease herpesvirus (MDV). " 03/01/1977 - "Chickens of line 7, highly susceptible to Marek's disease (MD), were depleted of T-cells by neonatal thymectomy, total-body gamma-irradiation, and multiple injections with antithymocyte serum. " 01/01/1982 - "Impaired host resistance against local JMV Marek's disease tumors after thymectomy and after bursectomy." 02/01/1979 - "Effect of thymectomy on the initial cytolytic lesions and nerve demyelination of Marek's disease."
3.	Drug Therapy (Chemotherapy) 01/01/2011 - "F-18 FDG PET/CT findings of a case of sacral nerve root neurolymphomatosis that occurred during chemotherapy." 08/01/2009 - "Reversal of neurological deficit after chemotherapy in BCL-6-positive neurolymphomatosis. " 06/01/2009 - "Neurolymphomatosis mimicking chemotherapy-induced ototoxicity." 08/01/2012 - "Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis."
4.	Injections 10/01/2002 - "Treatment of 2-week-old histocompatible B(13)/B(13) chickens highly susceptible to Marek's disease (MD) with rcMGF (two daily injections of 50 microg rcMGF per chicken) enhanced background and LPS-inducible systemic NO (NO3- + NO2-) responses 3 days later. " 03/01/1977 - "Chickens of line 7, highly susceptible to Marek's disease (MD), were depleted of T-cells by neonatal thymectomy, total-body gamma-irradiation, and multiple injections with antithymocyte serum. " 03/01/1984 - "Chickens aged one or 21 days were given single injections of a vaccine against Marek's disease or Newcastle disease respectively, and monitored over a three week period for any signs of a stressor response. "
5.	Transplantation (Transplant Recipients) 03/15/1980 - "The Marek's Disease virus-transformed, non-producer, lymphoma cell line, MDCC-RPI, was selected by sequential transplantation to produce a highly malignant variant, MDCC-ALI. " 12/01/1974 - "Transplantation of a Marek's disease lymphoma in syngeneic chickens."